Emerging Science Series - April 25, 2012

Protecting Cerebrovascular Function - From Translational Science to Clinical Trials

Wednesday, April 25, 2012, Noon–1:05 p.m.

  • Elliott Antman
  • Robert Harrington
  • Robert Bonow
  • John Murkin
  • Jeffrey Weitz 
  • Mark Clay


Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Analysis from the ROCKET AF Trial
Presenter: Jonathan P. Piccini, Duke Clinical Research Institute, Duke University Medical Center, Durham, N.C.
      Cerebrovascular Autoregulation Impairment is Associated with Elevations in Plasma Glial Fibrillary Acidic Protein During Congenital Heart Surgery  
Presenter: Ronald B. Easley, Baylor College of Medicine, Houston, Texas 
Posted by on Apr 27, 2012 9:44 AM America/Chicago